首页> 外文期刊>Antioxidants and redox signalling >Activation of Liver X Receptor Improves Viability of Adipose-Derived Mesenchymal Stem Cells to Attenuate Myocardial Ischemia Injury Through TLR4/NF-kappa B and Keap-1/Nrf-2 Signaling Pathways
【24h】

Activation of Liver X Receptor Improves Viability of Adipose-Derived Mesenchymal Stem Cells to Attenuate Myocardial Ischemia Injury Through TLR4/NF-kappa B and Keap-1/Nrf-2 Signaling Pathways

机译:肝脏X受体的激活改善了脂肪来源的间充质干细胞通过TLR4 /NF-κB和Keap-1 / Nrf-2信号通路减轻心肌缺血损伤的活力。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Aims: Clinical application of cellular therapy for cardiac regeneration is significantly hampered by the low retention of engrafted cells, mainly attributable to the poor microenvironment dominated by inflammation and oxidative stress in the host's infarcted myocardium. This study aims at investigating whether liver X receptor (LXR) agonist T0901317 will improve survival of adipose-derived mesenchymal stem cells (AD-MSCs) after transplantation into infarcted hearts. Results: Noninvasive in vivo bioluminescence imaging and histological staining showed that LXR agonist T0901317 improved the retention and survival of intramyocardially injected AD-MSCs. Moreover, combined therapy of LXR agonist and AD-MSCs inhibited host cardiomyocyte apoptosis, reduced fibrosis, and improved cardiac function, while it concomitantly decreased inflammatory cytokines (e.g., tumor necrosis factor-alpha and interleukin-6) and increased growth factor (e.g., vascular endothelial growth factor and basic fibroblast growth factor) expression in infarct myocardium. To reveal possible mechanisms, AD-MSCs were subjected to hypoxia/serum deprivation (H/SD) injury to simulate ischemic conditions in vivo. The LXR agonist (10(-7) mM) improved AD-MSC survival under H/SD condition. Western blot revealed that the LXR agonist reduced TLR4, TRAF-6, and MyD88 protein expression, inhibited I kappa B alpha phosphorylation and NF-kappa B-p65 nuclear translocation, which resulted in accelerated Keap-1 protein degradation, enhanced Nrf-2 nuclear translocation, and increased HO-1 protein expression. Innovation and Conclusion: LXR agonist can enhance the functional survival of transplanted AD-MSCs in infarcted myocardium, at least partially, via modulation of the TLR4/NF-kappa B and Keap-1/Nrf-2 signaling pathways. Moreover, combined therapy of LXR agonist and AD-MSCs has a synergetic effect on cardiac repair and functional improvement after infarction. Antioxid. Redox Signal. 21, 2543-2557.
机译:目的:移植细胞的滞留率低,严重阻碍了细胞疗法在心脏再生中的临床应用,这主要归因于宿主的梗死心肌的炎症和氧化应激所致的微环境差。这项研究旨在调查肝X受体(LXR)激动剂T0901317在移植到梗死心脏后是否会改善脂肪来源的间充质干细胞(AD-MSC)的存活率。结果:无创体内生物发光成像和组织学染色显示,LXR激动剂T0901317改善了心肌内注射的AD-MSC的保留和存活。此外,LXR激动剂和AD-MSC的联合治疗可抑制宿主心肌细胞凋亡,减少纤维化并改善心脏功能,同时减少炎症细胞因子(例如肿瘤坏死因子-α和白介素-6)并增加生长因子(例如,梗死心肌中血管内皮生长因子和碱性成纤维细胞生长因子的表达为了揭示可能的机制,AD-MSC经历了缺氧/血清剥夺(H / SD)损伤,以模拟体内缺血性疾病。 LXR激动剂(10(-7)mM)提高了H / SD条件下AD-MSC的存活率。 Western印迹显示LXR激动剂降低TLR4,TRAF-6和MyD88蛋白表达,抑制IκBα磷酸化和NF-κB-p65核易位,从而加速Keap-1蛋白降解,增强Nrf-2核易位,并增加HO-1蛋白表达。创新与结论:LXR激动剂可以通过调节TLR4 /NF-κB和Keap-1 / Nrf-2信号通路,至少部分地提高梗死心肌中AD-MSCs的功能存活率。此外,LXR激动剂和AD-MSC的联合治疗对梗死后的心脏修复和功能改善具有协同作用。抗氧化。氧化还原信号。 21,2543-2557。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号